|Bid||269.00 x 900|
|Ask||271.98 x 800|
|Day's range||266.29 - 271.91|
|52-week range||223.25 - 468.55|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||26.45|
|Earnings date||20 Oct 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||366.93|
Image source: The Motley Fool. Biogen inc (NASDAQ: BIIB)Q3 2021 Earnings CallOct 20, 2021, 8:00 a.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: OperatorGood morning.
Regulatory and pipeline updates from bigwigs like Regeneron (REGN) and Biogen (BIIB) have been the biotech sector's few key highlights during the past week.
Sage (SAGE) and partner Biogen are looking to get approval for zuranolone as an oral treatment for major depressive disorder. They will start rolling submission of an NDA in early 2022 for the candidate.